Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...
Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...
Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...
Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...
Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...
Novo Nordisk is lowering the price of its weight-loss drug Wegovy to $499 per month for some patients paying out of pocket. The deal is available through the drugmaker's new NovoCare Pharmacy offering ...
A popular weight-loss drug used by celebrities overseas has been approved by New Zealand’s medicine regulatory body, with its ...
(Reuters) -Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its ...
GlobalData on MSN7d
Novo Nordisk earmarks $2bn for Chinese “triple G” weight loss shotNovo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug ...
CNBC on MSN8d
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sureNovo Nordisk ... lose 15.7% of their weight over 68 weeks, compared with 3.1% with placebo. This was below the high-teens ...
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback